top of page
The Sound of Evolution
Bosutinib
Mechanism of action:
Bosutinib is an oral tyrosine kinase inhibitor. In cellular models carrying the chromosomal translocation t(9;22)(q34;q11), a BCR-ABL fusion gene is produced, generating a constitutively active ABL tyrosine kinase. Bosutinib directly binds to the ATP-binding site of the BCR-ABL kinase, inhibiting downstream signaling pathways, blocking cell proliferation, and affecting pathways related to cell survival.
Reference(s):
1. Amsberg GK et al. (2013). Bosutinib in the management of chronic myelogenous leukemia. Biologics.
2. Keller-V Amsberg G et al. (2012). Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia. Expert Rev Anticancer Ther.
bottom of page